Skip to main content

Advertisement

Table 3 Impact of on-treatment HBV DNA on 5-year outcomes

From: Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-Year prospective study

  N VR P-value HBeAg loss P-value HBeAg seroconversion P-value
drop of HBV DNA ≥3 log10copies/ml at week 4 12 91.7% 0.06 91.7% 0.013 41.7% 0.083
drop of HBV DNA < 3 log10copies/ml at week 4 35 62.6%   51.4%   17.1%  
drop of HBV DNA ≥4 log10copies/ml at week 12 20 85.0% 0.366 80.0% 0.028 45.0% 0.006
drop of HBV DNA < 4 log10copies/ml at week 12 27 60.0%   48.0%   7.4%  
DNA level < 4 log10copies/ml at week 24 25 96.0% < 0.001 84.0% 0.001 36.0% 0.030
DNA level ≥ 4 log10copies/ml at week 24 22 40.9%   36.3%   9.1%  
DNA negative at week 52 27 100% < 0.001 88.9% < 0.001 33.3% 0.062
DNA positive at week 52 20 45.0%   20.0%   10.0%